WCN24-AB-912

IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy

Jonathan Barratt,[1] Jürgen Floege,[2] Vishal Duggal,[3] Nadine Schmit,[4] Ji Cheng,[5] Jeannette Lo,[3] Brad H. Rovin[6]

[1]Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; [2]Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany; [3]Genentech, Inc., South San Francisco, CA, USA; [4]F. Hoffmann-La Roche Ltd, Basel, Switzerland; [5]Hoffmann-La Roche Ltd, Mississauga, ON, Canada; [6]Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA

BACKGROUND AND OBJECTIVE

- IgA nephropathy (IgAN) is a chronic, progressive autoimmune disease and is the most common cause of primary glomerulonephritis worldwide[1,2]
  - Approximately 25% to 30% of patients with IgAN develop kidney failure within 20 to 25 years of presentation[3]
- Current treatments include blood pressure control through inhibition of the renin-angiotensin system and lifestyle modifications[3]
- IgAN is a multi-hit disease in which immune complexes of galactose-deficient IgA1 and associated autoantibodies accumulate in the kidney and trigger activation of the alternative complement pathway[1]
  - Factor B is a key protease in the activation and amplification of the alternative complement pathway, and serum levels of factor B are increased in patients with IgAN[4]
  - Overactivation of the alternative complement pathway has been implicated in the pathogenesis and severity of IgAN[5]
- RO7434656 (IONIS-FB-LRx; ISIS 696844), a ligand-conjugated antisense oligonucleotide targeting complement factor B messenger RNA (mRNA), was engineered for enhanced delivery to the liver as the primary site of factor B production (**Figure 1**)
  - RO7434656 binds to and destroys complement factor B mRNA, reducing production of factor B protein
  - In an initial data cut (April 2023) of a Phase 2 trial (NCT04014335), RO7434656 inhibited alternative complement pathway activation and demonstrated a clinically meaningful reduction in the urine protein-to-creatinine ratio (UPCR; **Figure 2**) and stabilization of the estimated glomerular filtration rate (eGFR) in patients with IgAN[6]
    - RO7434656 was generally well-tolerated, with no serious adverse events

Objective

- To evaluate the efficacy, safety and pharmacokinetics of RO7434656 compared with those of placebo in adults with biopsy-confirmed primary IgAN

METHODS

Study design and participant population

- IMAGINATION (NCT05797610) is a Phase 3, randomized, double-blind, placebo-controlled trial (**Figure 3**)
- Participants will be randomized 1:1 to either RO7434656 or matching placebo administered as a subcutaneous injection every 4 weeks for 105 weeks
  - After 105 weeks, participants will have the opportunity to continue double-blind treatment or switch to open label treatment
  - After the first 8 doses of the study treatment, administration may be completed by the participant or another caregiver at their home or other suitable location upon completion of training
- The study will be conducted at approximately 225 sites globally (**Figure 4**)
- Key inclusion and exclusion criteria are shown in **Table 1**
- Primary, secondary and exploratory endpoints are shown in **Table 2**

Statistical analysis

- The sample size was calculated to provide approximately 90% power and detect a 30% difference in the primary endpoint between RO7434656 and placebo groups at a 2-sided 0.025 (α) significance level
- The primary analysis is based on Week 37 assessments and updated analyses on Week 105 assessments

CONCLUSIONS

- IMAGINATION aims to evaluate the efficacy and safety of RO7434656 in adults with IgAN using a broad range of assessments over 105 weeks
- The unique antisense modality and long tissue half-life of RO7434656 enables monthly subcutaneous administration to inhibit the alternative complement pathway

RO7434656 AND THE IMAGINATION TRIAL

Figure 1. Mechanism of Action of RO7434656



ASO, antisense oligonucleotide; ASGPR, asialoglycoprotein receptor; GalNac, N-acetyl-d-galactosamine; mRNA, messenger RNA; RNase, ribonuclease.

Figure 2. Change in (**A**) Factor B, (**B**) Key Complement Parameters and (**C**) UPCR From an Initial Data Cut (April 2023) of a Phase 2 Trial of RO7434656 (NCT04014335)[6]* in Patients With IgAN (n=13)



Barbour S, et al. Presented at the American Society of Nephrology (ASN) Kidney Week 2023; November 1-5, 2023; Philadelphia, PA, USA. Poster SA-PO926. Images reprinted with permission from the author.

IgAN, IgA nephropathy; ET, early termination; LLN, lower limit of normal; SGLT2, sodium glucose cotransporter 2; ULN, upper limit of normal; UPCR, urine protein-to-creatinine ratio.

*Study sponsor is Ionis Pharmaceuticals, Inc. Patients received subcutaneous injections of RO7434656 70 mg at Weeks 1, 3, 5, and every 4 weeks thereafter. †One patient discontinued study drug after 4 months of treatment (last dose at Week 17) to initiate SGLT-2 inhibitors. ‡Additional complement sampling time points following protocol amendment.

Figure 3. Study Design of the Phase 3 IMAGINATION Trial (NCT05797610)



Trial highlights

- Only antisense oligonucleotide inhibitor in Phase 3 trial in nephrology
- Exploratory cohort with lower eGFR criteria
- Optional biopsies at baseline and Weeks 37 and/or 105
- Unique antisense modality enables Q4W dosing
- Mobile nursing visits and self-administration option

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; ERA, endothelin receptor antagonist; IgAN, IgA nephropathy; PK, pharmacokinetic; PRO, patient-reported outcome; Q4W, every 4 weeks; R, randomized; RAS, renin-angiotensin system; SGLT2, sodium glucose cotransporter 2; SOC, standard of care; UPCR, urine protein-to-creatinine ratio.

*Stable doses of SGLT2 inhibitors, ERAs, or other agent(s) for BP management permitted. †Self-administration by participant or caregiver permitted after first 8 doses. Average on-site visits every 12 weeks, with the option of mobile nursing visits. Biomarker, blood and urine samples to be collected throughout the study. ‡SOC includes ACE inhibitor or ARB at maximum tolerated approved dose with or without SGLT2 inhibitors, ERAs or other agent(s) for BP management.

Figure 4. Enrollment Sites



- Approximately 225 sites will participate in the study

Table 1. Key Inclusion and Exclusion Criteria

Key Inclusion Criteria
Diagnosed with primary IgAN as evidenced by a kidney biopsy performed within 7 years prior to or during screening
Previous treatment with maximum tolerated doses of ACE inhibitors or ARBs for ≥90 days immediately prior to screening
UPCR ≥1 g/g or urine protein excretion ≥1 g/day (with UPCR ≥0.8 g/g) from a 24-hour collection
eGFR ≥30 mL/min/1.73 m² (primary cohort)* or ≥20 and <30 mL/min/1.73 m² (exploratory cohort)*
Age ≥18 years at the time of signing of informed consent form
Vaccination against *Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae*†
Key Exclusion Criteria
Histopathologic or other evidence of another autoimmune glomerular disease
Presence of ≥50% crescents in kidney biopsy, sustained doubling of serum creatinine level within 3 months prior to screening or rapidly progressive glomerulonephritis in the opinion of the investigator
Hemoglobin A1c ≥6.5% or a clinical diagnosis of diabetes mellitus of any type
Treatment with oral or IV corticosteroids with a dose equivalent to ≥7.5 mg/day of prednisone for 7 days or ≥5 mg/day of prednisone for 14 days within 90 days prior to screening
Treatment with oral or IV corticosteroids during screening

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; IgAN, IgA nephropathy; IV, intravenous; UPCR, urine protein-to-creatinine ratio.

*eGFR calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine equation. †If vaccination must be administered during screening, it must occur ≥2 weeks prior to the first dose of RO7434656.

Table 2. Primary, Secondary and Exploratory Endpoints

Primary Endpoint
Change in proteinuria from baseline as measured by geometric mean change of **UPCR at Week 37** from a 24-hour collection
Secondary Endpoints
Total eGFR* slope at Week 105
Change in symptoms and health-related QOL at Week 105 compared with baseline as assessed by the Kidney Disease Quality of Life 36-Item Short Form survey
Time to first composite kidney failure endpoint†
Change in fatigue at Week 105 compared with baseline as assessed by the Functional Assessment of Chronic Illness Therapy–Fatigue Scale
Plasma concentrations of RO7434656
Incidence and severity of treatment-emergent adverse events
Exploratory Endpoints
Exploratory biomarker assessments

eGFR, estimated glomerular filtration rate; QOL, quality of life; UPCR, urine protein-to-creatinine ratio. *eGFR calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine equation.†Defined as receipt of kidney transplant, need for kidney replacement therapy or sustained decline in eGFR of ≥30%.

REFERENCES

1. Suzuki H, et al. *J Am Soc Nephrol*. 2011;22(10):1795-1803.
2. McGrogan A, et al. *Nephrol Dial Transplant*. 2011;26(2):414-430.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group; Rovin BH, et al. *Kidney Int*. 2021;100(4 suppl):S1-S276.
4. van den Wall Bake AW, et al. *Am J Kidney Dis*. 1988;12(5):410-414.
5. Medjeral-Thomas NR, et al. *Semin Immunopathol*. 2021;43:679–690.
6. Barbour S, et al. Presented at the American Society of Nephrology (ASN) Kidney Week 2023; November 1-5, 2023; Philadelphia, PA, USA. Poster SA-PO926.

DISCLOSURES

J. Barratt has received consulting/speaker fees from Alnylam, Argenx, Astellas, BioCryst, Calliditas Therapeutics, Chinook, Dimerix, Galapagos, Novartis, Omeros, Travere Therapeutics, Vera Therapeutics and Visterra; and grant support from Argenx, Calliditas Therapeutics, Chinook, Galapagos, GSK, Novartis, Omeros, Travere Therapeutics and Visterra., **J. Floege** has received consultancy and/or speaker honoraria from AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere and Vera Therapeutics. **V. Duggal** and **J. Lo** are employees of Genentech, Inc. **N. Schmit** and **J. Cheng** are employees of F. Hoffmann-La Roche Ltd. **B.H. Rovin** has received consulting fees from Roche/Genentech.

Ionis Pharmaceuticals discovered ASO Factor B and is partnered with F. Hoffmann-La Roche Ltd for its development.

This study is sponsored by F. Hoffmann-La Roche Ltd. Support for third-party writing assistance, provided by Samantha O'Dwyer, PhD, of Nucleus Global was funded by F. Hoffmann-La Roche Ltd.

An electronic version of this poster may be obtained by scanning this QR code with your smartphone app

More information on IMAGINATION may be obtained by scanning this QR code with your smartphone app

Presented at: World Congress of Nephrology 2024 (WCN'24); April 13-16, 2024: Buenos Aires, Argentina.